Electra Therapeutics, Inc.
ETRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002088082
In the last 90 days, Electra Therapeutics, Inc. insiders filed 3 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Electra Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 3 filings
- 1 insider, $24.3M in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$24.3M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Electra Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Gordon Carl L | Director, 10% Owner | 2,194,579Indirect | Nov 10, 2026 | 3 |
| OrbiMed Advisors LLC | Director, 10% Owner | 2,194,579Indirect | Nov 10, 2026 | 3 |
| OrbiMed Capital GP VII LLC | Director, 10% Owner | 2,194,579Indirect | Nov 10, 2026 | 3 |
| OrbiMed Genesis GP LLC | Director, 10% Owner | 2,194,579Indirect | Nov 10, 2026 | 3 |
| Koe Gary S. | Chief Technical Officer | 63,656 | Sep 21, 2026 | 1 |
| Stagliano Nancy | Director | 255,635 | Sep 21, 2026 | 1 |
| Parry Graham | Chief Scientific Officer | 85,504 | Sep 21, 2026 | 1 |
| Dong Quehuong (Kathy) | President & CEO | 455,484 | Sep 21, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2026 (view filing)8:14 PM ET | Nov 6-10 | 4 days | Gordon Carl LDirector, 10% Owner | PPurchase | +92.1K | $8.08 | +$744.5K | +4.4%2.19M after | 6 lotsDuplicate filing |
| Nov 10, 2026 (view filing)8:09 PM ET | Nov 6-10 | 4 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +92.1K | $8.08 | +$744.5K | +4.4%2.19M after | 6 lots |
| Nov 5, 2026 (view filing)5:47 PM ET | Nov 3-5 | 2 days | Gordon Carl LDirector, 10% Owner | PPurchase | +472.6K | $7.63 | +$3.61M | +28.4%2.14M after | 10 lotsDuplicate filing |
| Nov 5, 2026 (view filing)5:39 PM ET | Nov 3-5 | 2 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +472.6K | $7.63 | +$3.61M | +28.4%2.14M after | 10 lots |
| Sep 23, 2026 (view filing)5:35 PM ET | Sep 21 | 2 days | Gordon Carl LDirector, 10% Owner | PPurchase | +1.33M | $15.00 | +$20.0M | +313.8%1.76M after | 2 lotsDuplicate filing |
| Sep 23, 2026 (view filing)5:29 PM ET | Sep 21 | 2 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +1.33M | $15.00 | +$20.0M | +313.8%1.76M after | 2 lots |